biostudies-literatureRyan CJNCI NIH HHS2791-8https://www.ebi.ac.uk/biostudies/studies/S-EPMC5569674biostudies-literatureUnknown31(22)<h4>Purpose</h4>In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we investigate the relationship between baseline serum androgen (SA) levels and OS.<h4>Patients and methods</h4>COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by mouth twice daily; n = 797) versus P alone (n = 398). Randomization was stratified by Eastern Cooperative Oncology Group performance status (0 to 1 v 2), pain (Brief Pain Inventory-Short Form over past 24 hours: 4 to 10, present; v 0 to 3, absent), prior chemotherapy (1 v 2), and progression (prostate-specific antigen v radiographic). AssociationJournal of clinical oncology : official journal of the American Society of Clinical OncologySerum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.PMC5569674P30 CA008748Ryan CJGrant RPLi JHaqq CMMolina Ade Bono JSScher HIKheoh TSmall EJfalseSerum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.<h4>Purpose</h4>In the phase III study COU-AA-301, abiraterone acetate (AA) plus prednisone (P) prolonged overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel administration. In this article, we investigate the relationship between baseline serum androgen (SA) levels and OS.<h4>Patients and methods</h4>COU-AA-301 is a randomized, double-blind study of AA (1,000 mg every day) plus P (5 mg by mouth twice daily; n = 797) versus P alone (n = 398). Randomization was stratified by Eastern Cooperative Oncology Group performance status (0 to 1 v 2), pain (Brief Pain Inventory-Short Form over past 24 hours: 4 to 10, present; v 0 to 3, absent), prior chemotherapy (1 v 2), and progression (prostate-specific antigen v radiographic). Association2013-01-01T00:00:00Z2013 Aug2025-04-04T09:53:52.442Z2019-03-27T02:54:24ZS-EPMC55696742381696410.1200/jco.2012.45.459510.1200/JCO.2012.45.4595